- Home
- AUPH vs BCRX Comparison
AUPH vs BCRX Comparison
Compare AUPH & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | BCRX |
|---|---|---|
| Founded | 1993 | 1986 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1999 | 1994 |
Fundamental Metrics
Financial Performance| Metric | AUPH | BCRX |
|---|---|---|
| Price | $14.78 | $7.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $17.25 | ★ $20.82 |
| AVG Volume (30 Days) | 939.1K | ★ 4.4M |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | $265,808,000.00 | ★ $599,816,000.00 |
| Revenue This Year | $21.76 | $39.83 |
| Revenue Next Year | $16.45 | $5.47 |
| P/E Ratio | $27.01 | ★ N/A |
| Revenue Growth | 20.62 | ★ 45.38 |
| 52 Week Low | $6.55 | $6.00 |
| 52 Week High | $16.54 | $11.31 |
Technical Indicators
Market Signals| Indicator | AUPH | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 46.76 |
| Support Level | $14.36 | $6.46 |
| Resistance Level | $15.19 | $7.27 |
| Average True Range (ATR) | 0.49 | 0.38 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 24.06 | 35.85 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.